A meprin protease inhibitor and assay platform developed at Fraunhofer IZI are the basis for the research collaboration with Vivoryon Therapeutics AG. Headed by PD Dr. Stephan Schilling, the Department of Drug Design and Target Validation will work with the company to develop first-class small molecule meprin inhibitors. The aim is to develop therapeutic applications for fibrosis, cancer and Alzheimer's disease.